Infectious diseases are among the leading causes of notable burden worldwide in healthcare industry. The disease are also termed as communicable diseases or transmissible diseases that are caused by several infectious agents such bacteria, virus, viroids; nematodes including pinworms and parasitic roundworms; arthropods including ticks, mites, lice, fleas; fungi including ringworm; other macroparasites including tapeworms along with other helminths. Developments of several technologically advanced options for treatment and diagnosis and enhancements in vaccination, antimicrobial therapy, and hygiene, have reduced the deaths lead by infectious diseases. However, re-emergence and emergence of infectious disease substantially affects the outcomes of health of the global population.
Global Infectious Disease Therapeutics Market Drivers
Rising incidence of infectious diseases, rising awareness related to early detection of infectious diseases, along with increasing activities of research funding from various government and private organization are factors expected to drive growth of the global infectious disease therapeutics market over the forecast period. For instance, as per the 2015 data findings by the National Ambulatory Medical Care Survey, 16.8 Mn visits at physician offices to treat parasitic and infectious diseases were recorded in the U.S. As per the same source, from September 2012, over 2,143 cases of MERS-CoV infection were laboratory-confirmed.
Get Sample Report With Covid-19 impact analysis: https://www.coherentmarketinsights.com/insight/request-sample/1658
The World Health Organization (WHO) stated that the GISRS (Global Influenza Surveillance and Response System) laboratories, during April 2, 2018 till April 15, 2018, analyzed over 137,071 samples from several National Influenza centers (NIC) along with other national influenza laboratories from 113 countries. From such collected specimens, over 21,639 were influenza virus positive, in which 12,034 (55.6%) were characterized for influenza A and 9,605 (44.4%) for influenza B. As per the Centers for Disease Control and Prevention (CDC), over 5,251 deaths owing to infection of influenza were registered in 2015, in the U.S. As per the World Health Organization (WHO), over 32,000 estimated fatalities from tuberculosis as well as over 3, 23,000 new TB cases were registered, in 2015, in Europe. As per the European Centre for Disease Prevention and Control (ECDC), published data, in February 2018, over 44,000 people lose their lives every year due to respiratory diseases related to seasonal influenza within Europe, from a total of over 6,50,000 deaths globally every year.
Furthermore, rising advancements in quick diagnosis of several infectious diseases is having a great impact on medical outcomes of the disease treatment. Modern technologies including agglutination assays, lateral flow, and solid phase used in infectious diseases rapid diagnostics are coupled with novel features including handheld device portability, providing point-of-care treatment for the patients. Furthermore, technological advancements in point-of care diagnostics are expected to propel growth of the global infectious disease therapeutic market during the forecast period. For instance, Becton, Dickinson, and Company, in 2014, provided point-of-care system for HIV/AIDS, BD FACSPresto. This provides hemoglobin concentration and percentage results of the CD4 T lymphocytes. Furthermore, Infectious Disease Research Institute (IDRI), in January 2017, developed the fusion antigen that are used as diagnostic tests manufactured by the InBios International, Inc. for the Chagas disease.
Buy This Premium Research Report With Discount of USD 2000 Flat Off: https://www.coherentmarketinsights.com/promo/buynow/1658
Furthermore, research funding by several private and government organizations for infectious diseases for providing effective treatment and diagnostic options. For instance, QuantuMDx Group, in November 2016, was funded by the Bill & Melinda Gates Foundation for developing and testing Q-POC molecular diagnostic platform and CAPTURE-XT pathogen concentration technology by the company for quick low cost tuberculosis detection. The University of Glasgow-led project, in January 2018, received funding of US$ 1.85 Mn, which is the part of the Global Challenges Research Fund (GCRF). The project will be developing novel tests for the parasitic diseases along with quick testing in remote locations for helping enable quick diagnosis and quick treatments of the infectious diseases.
Global Infectious Disease Therapeutics Market Restraints
Absence of awareness regarding treatments for diseases, low treatment adoption, lack of reimbursement of some infectious diseases within selected nations are factors, expected to hamper growth of the global infectious disease therapeutics market during the forecast period. Furthermore, Asia and Africa have high prevalence of infectious disorders along with low rate of penetration of treatments. For instance, in 2015, as per AVERT, a global AIDS & HIV aids U.K.-based charity organization, 6.5 Mn individuals suffered from Human Immunodeficiency Virus (HIV) in region of Central and West Africa and over 28% HIV infected individuals were accessing the antiretroviral therapy. Moreover, rising counterfeit drug availability in Asian nations is expected to restrain growth of the global infectious disease therapeutics market over the forecast period.
Infectious Disease Therapeutics Market – Regional Analysis
Based on region, the global infectious disease therapeutics market is segregated into North America, Europe, Latin America, Middle East, Africa, and Asia Pacific. North America accounts for the highest share in the global infectious disease therapeutics market, preceding Europe. This is owing to rising R&D studies by several pharmaceutical and government organizations for infectious disease and its diagnosis. Moreover, high awareness and prevalence of infectious diseases in people, who turn opt for early diagnosis, is expected to propel growth of the global infectious disease therapeutics market within the region. For instance, as per the Centers for Disease Control and Prevention (CDC), over 26,203 Lyme disease cases were reported in the U.S from 2006 to 2016. In 2015, as per the similar source, over 10,265 death cases were recorded due to driving crashes that were alcohol-impaired, accounting for over 29% among all the traffic-related fatalities in the U.S.
Asia Pacific is expected to register robust growth during the forecast period in the global infectious disease therapeutics market, owing to rising demands for quick and efficient diagnostic testing, rising number of market players adopting strategies for expanding their reach within the region, as well as initiatives by government organizations to minimize the burden of disease are factors, expected to propel growth of the global infectious disease therapeutics market in Asia Pacific. For instance, Qiagen N.V., in March 2013, in China, launched the careHPV test. The CareHPV test is a molecular diagnosis designed for screening high risk human papillomavirus (HPV) in settings of low-resource including areas with no water, electricity, or laboratories. The Qiagen also received approval from the State Food and Drug Administration (SFDA) in China, in 2012, for careHPV. Moreover, Government of India, in March 2018, introduced the TB Free India Campaign aiming to eliminate tuberculosis (TB) completely by 2025.
Global Infectious Disease Therapeutics Market – Competitive Landscape
Major players functioning in the global infectious disease therapeutics market are Gilead Sciences, Inc., Janssen Pharmaceutical, GlaxoSmithKline plc, BioCryst Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, and others. Major players are focused on development of new products to treat infectious diseases as well as are also getting approved for commercializing their products. For instance, Merck, in May 2017, received the approval of U.S. FDA for the ISENTRESS HD, a latest integrase inhibitor of 1200 mg for patients infected by HIV-1. This drug could also be utilized in combination therapies with the other antiretrovirals.
Global Infectious Disease Therapeutics Market – Taxonomy
By Mode of Treatment
-
Drugs
-
Injections
-
Topical
-
Oral Administration
-
Others
-
-
Vaccines
Based on Drug Class
-
Anti-Viral
-
Anti-Bacterial
-
Anti-Fungal
-
Anti-Parasite
-
Others
Based on Disease Indication
-
HIV/AIDS
-
Tuberculosis
-
Hepatitis
-
Influenza
-
Others
Based on End User
-
Retail Pharmacy
-
Hospital Pharmacy
-
Others
Based on Region
-
North America
-
Europe
-
Latin America
-
Asia Pacific
-
Africa
-
Middle East
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837